尚未调查不同亚型和肺癌分期对致残率和病死率的生产力影响。本研究对不同亚型和肺癌分期的患者的终身就业期限和生产力损失进行了量化。我们识别了在2011年至2019年间，年龄在50-64岁之间被诊断为全国肺癌患者。根据月度就业人口比例和工资来加权月度生存概率，以估计终身就业期限和生产力。我们将患者的终身就业期限和生产力与年龄、性别、日历年匹配的一般人口进行比较，计算终身就业期限和生产力的损失，然后根据台湾非吸烟者肺癌筛查试验（TALENT）首轮筛查的病理学和分期转变对终身就业期限和生产力的节约进行计算。肺癌患者的生存时间和就业期限较短，与参考组相比。非腺癌肺癌患者的终身就业期限和生产力损失较腺癌患者更大。将非吸烟患者的估算应用于基于TALENT的病理学和分期转变的100名肺癌患者，终身就业期限和生产力的节约分别为132.2（95％预测区间：116.2-147.4）年和3353（95％预测区间：2914-3802）千美元。早期诊断肺癌将节约就业期限和终身生产力的损失。未来肺癌筛查的成本效益评估可以考虑纳入这些社会影响。 © 2023. 作者。

How different subtypes and stages of lung cancer affect morbidity- and mortality-associated productivity have not been investigated. This study quantified the losses of lifetime employment duration and productivity among patients with various subtypes and stages of lung cancer.We identified nationwide lung cancer patients diagnosed at the ages of 50-64 between 2011 and 2019. Monthly survival probabilities were weighted by monthly employed-to-population ratios and working salaries to estimate lifetime employment duration and productivity. We compared lifetime employment duration and productivity of patients with those of the age-, sex-, calendar year-matched general population for losses of lifetime employment duration and productivity, which were multiplied by pathology and stage shifts based on the first-round screening of Taiwan Lung Cancer Screening in Never Smoker Trial (TALENT) to calculate the savings of lifetime employment duration and productivity.Lung cancer patients had shorter survival and employment duration than the referents. Patients with lung cancers other than adenocarcinoma experienced greater losses of lifetime employment duration and productivity as compared to adenocarcinoma patients. Applying the estimations of never-smoking patients to 100 lung cancer patients with pathology and stage shifts based on the TALENT, the savings of lifetime employment duration and productivity were 132.2 (95% prediction interval: 116.2-147.4) years and 3353 (95% prediction interval: 2914-3802) thousand US dollars, respectively.Early diagnosis of lung cancer would save the losses of employment duration and lifetime productivity. Future evaluation of the cost-effectiveness of lung cancer screening could consider incorporating these societal impacts.© 2023. The Author(s).